silybin has been researched along with Cancer of Kidney in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| AbouZid, SF; Ahmed, OM; Ali, TM; Almoiliqy, M; An, S; Anggraeni, AT; Bailón-García, E; Bueno-López, A; Buyze, J; Chen, DQ; Chen, X; Davó-Quiñonero, A; De Weggheleire, A; Ding, Z; El-Kalaawy, AM; Elesawy, BH; Francque, S; Gao, F; Guo, Y; Juan-Juan, J; Li, S; Li, Y; Lin, Y; Liu, X; Liu, Z; Lozano-Castelló, D; Lu, X; Lynen, L; Meng, Q; Peng, J; Ran, Y; Razali, MH; Rodríguez, SL; Shen, MJ; Soedarsono, S; Soeprijanto, B; Su, W; Sun, P; Tang, AL; Thai, S; Tian, G; Topîrceanu, A; van Griensven, J; Wang, H; Wang, Y; Wen, J; Xi, J; Xiong, MC; Yang, S; Yang, X; Yassin, NYS; Ye, L; Yusoff, M; Zhang, GQ; Zhang, Y | 1 |
| Guo, P; He, D; Jia, J; Li, F; Ma, J; Wang, X; Yang, C; Zeng, J; Zhang, HB | 1 |
| Dan, W; Fan, Y; Hou, T; Li, L; Liu, B; Liu, T; Luan, J; Zeng, J | 1 |
| Shende, P; Takke, A | 1 |
| Chen, Y; Guan, Z; Guo, P; He, D; Li, F; Ma, Z; Wang, X; Wu, K; Zeng, J | 1 |
| Chang, LS; Guo, P; He, D; Li, L; Liu, W; Ma, Z; Wang, X; Xie, H; Xu, S; Yang, Z; Zeng, J; Zheng, L; Zhou, J | 1 |
| Agarwal, R; Chittezhath, M; Deep, G; Raina, K; Rajamanickam, S; Singh, RP | 1 |
| Gao, Y; He, D; Li, L; Sun, Y; Zeng, J; Zhang, L | 1 |
| Chang, HR; Chen, PN; Chu, SC; Hsieh, YS; Hung, TW; Lian, JD; Sun, YS; Wu, SW; Yang, SF | 1 |
| Chang, LS; Chen, YL; Gao, Y; He, D; Li, L; Liang, L; Wang, XY; Wang, ZQ; Zeng, J | 1 |
| Cheung, CW; Johnson, DW; Nicol, DL; Vesey, DA | 1 |
| Cheung, CW; Gobe, GC; Johnson, DW; Kirkpatrick, CM; Nicol, DL; Taylor, PJ; Vesey, DA; Winterford, C | 1 |
12 other study(ies) available for silybin and Cancer of Kidney
| Article | Year |
|---|---|
Topics: Acute Lung Injury; Adherens Junctions; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antigens, CD; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; beta Catenin; Brain Ischemia; Cadherins; Carcinogenesis; Catalysis; Cell Line; Cells, Cultured; Curcuma; Curcumin; Dioxoles; Disease Models, Animal; Endothelial Cells; Epithelial Cells; Heme Oxygenase (Decyclizing); Humans; Inflammasomes; Intestinal Diseases; Intestinal Mucosa; Ischemic Stroke; Kidney Neoplasms; Lignans; Lung; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; NAD(P)H Dehydrogenase (Quinone); Nanostructures; NF-E2-Related Factor 2; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Pneumonia; PPAR gamma; Proto-Oncogene Proteins c-akt; Pyroptosis; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reperfusion Injury; Respiratory Distress Syndrome; Sepsis; Sesamum; Signal Transduction; Silybin; Silybum marianum; Silymarin; Sirtuin 3; Titanium; Transfection; Treatment Outcome; White Matter | 2021 |
Evaluation of anti-cancer potency of silibinin on murine renal carcinoma RenCa cells in an animal model with an intact immune system.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Humans; Immune System; Kidney Neoplasms; Mice; Silybin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Silibinin inhibits epithelial‑mesenchymal transition of renal cell carcinoma through autophagy‑dependent Wnt/β‑catenin signaling.
Topics: Animals; Apoptosis; Autophagy; beta Catenin; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Silybin; Wnt Signaling Pathway | 2020 |
Magnetic-core-based silibinin nanopolymeric carriers for the treatment of renal cell cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Carriers; Humans; Kidney Neoplasms; Magnetite Nanoparticles; Silybin; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman | 2021 |
Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
Topics: Adenylate Kinase; Antineoplastic Agents; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Drug Screening Assays, Antitumor; Humans; Kidney Neoplasms; Signal Transduction; Silybin; Silymarin; TOR Serine-Threonine Kinases | 2015 |
Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Silybin; Silymarin; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2015 |
Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Body Weight; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasm Staging; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma.
Topics: Antioxidants; Apoptosis; Carcinoma, Renal Cell; Caspases; Cell Death; Cell Division; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Genes, p53; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Microtubule-Associated Proteins; Silybin; Silymarin; Survivin; Up-Regulation | 2008 |
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; HEK293 Cells; Humans; Kidney Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred ICR; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Paclitaxel; Silybin; Silymarin; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2011 |
Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kidney Neoplasms; Lymphatic Metastasis; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Phosphorylation; Protein Processing, Post-Translational; Signal Transduction; Silybin; Silymarin | 2012 |
Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Blotting, Western; Carcinoma, Renal Cell; Drug Screening Assays, Antitumor; Humans; Insulin-Like Growth Factor Binding Protein 3; Kidney Neoplasms; Silybin; Silymarin; Tumor Cells, Cultured; Up-Regulation | 2007 |
Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels.
Topics: Administration, Oral; Analysis of Variance; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Renal Cell; Insulin-Like Growth Factor Binding Protein 3; Kidney Neoplasms; Male; Mice; Mice, SCID; Reverse Transcriptase Polymerase Chain Reaction; Silybin; Silymarin | 2007 |